VolitionRx Completes $1.9 Million Registered Direct Offering

Stradling represented VolitionRx, a company which, through its subsidiaries, is developing and commercializing simple, easy-to-use, cost-effective blood tests to diagnose and monitor a range of diseases, including some cancers, diseases associated with NETosis and sepsis, in raising $1.9 million through the sale of Common Stock, plus and up to an additional $2.7 million upon the future exercise of warrants.